Anticipate generic drug launch
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content|
|Abstract:||Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.|
|Inventor(s):||Boss; Anders Hasager (Princeton, NJ), Petrucci; Richard (New Canaan, CT), Howard; Campbell (Yardley, PA), Mann; Alfred (Valencia, CA)|
|Assignee:||MannKind Corporation (Valencia, CA)|
1. A method of controlling glycemia related to one or more daily meals in an individual with diabetes without adjusting an insulin dose for meal content comprising the step
of administering a standard dosage of an ultrarapid acting insulin formulation at a mealtime for one or more of the daily meals, wherein, for any given daily meal, the standard dosage for the daily meal has been predetermined based on said individual's
usual meal content for the daily meal, and wherein, at least occasionally, content of the daily meal varies from .gtoreq.25% to .ltoreq.250% of the individual's usual meal content, and the standard dosage is not adjusted when a meal is consumed that
varies from .gtoreq.25% to .ltoreq.250% of the individual's usual meal content as used in the determination of the standard dosage.
2. The method of claim 1 wherein the ultrarapid-acting insulin formulation is insulin-FDKP.
3. The method of claim 1 wherein a standard dosage is administered at each mealtime.
4. The method of claim 1 wherein a single predetermined dosage is used for each mealtime.
5. The method of claim 1 wherein a predetermined dosage is set for each mealtime.
6. The method of claim 1 wherein meal content is assessed as glycemic load.
7. The method of claim 1 wherein meal content is assessed as caloric content.
8. The method of claim 1 wherein meal content is .gtoreq.25% of a usual meal content as used in predetermination of the standard dose.
9. The method of claim 8 wherein meal content is .gtoreq.50% of a usual meal content as used in predetermination of the standard dose.
10. The method of claim 1 wherein meal content is .ltoreq.200% of a usual meal content as used in predetermination of the standard dose.
11. The method of claim 10 wherein meal content is .ltoreq.150% of a usual meal content as used in predetermination of the standard dose.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.